Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
- 1327.389
- -39.880-2.92%
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday
12 Health Care Stocks Moving In Thursday's After-Market Session
Sangamo Therapeutics Stock Surges After The Bell: What's Going On?
CRISPR Therapeutics Set to Snap Six Straight Sessions of Losses
Scotiabank Maintains Sector Perform on Apellis Pharmaceuticals, Raises Price Target to $31
Apellis Pharmaceuticals Analyst Ratings
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals
Is Vertex Pharmaceuticals Gaining or Losing Market Support?
Apellis Pharmaceuticals Shares Are Trading Higher After the Company Announced FDA Acceptance, Priority Review of SNDA for EMPAVELI.
CVS, COR, Among Top S&P 500 Healthcare Gainers in Q1; WST and MRNA Among Losers
Nasdaq 100 Logs Worst Quarter in Three Years - Here's What's Driving the Drop
Cantor Analysts Call for RFK Jr. Replacement Following Ousting of Marks at FDA
S&P 500 Exits Q1 in the Red - Here Are Its Largest Losers and Winners
BlueBird Shares Are Up Today: What's Going On?
Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data
12 Health Care Stocks Moving In Monday's Intraday Session
How Peter Marks' FDA Departure Is Impacting Pharma, Biotech Stocks
Vertex Non-opioid Painkiller Journavx Gets Mixed ICER Review
Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps